MNKD catalyst calendar

MANNKIND CORP

Upcoming catalysts
3
Cash runway
62.1 months
Cash & investments
$111M
Phase 3 programs
2

MANNKIND CORP is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 62.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 53 concluded trials, 85% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 4, 2026 est. Next quarterly earnings (projected) Earnings —
March 15, 2027 INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes Trial Milestone Phase 2
December 30, 2027 Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Trial Milestone Phase 2

Track MNKD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open MNKD in the tracker

Recent history

DateEventTypePhase
August 21, 2026 8-K filed: Other event Filing —
August 5, 2026 Quarterly results filed (8-K) Earnings —
July 24, 2026 8-K filed: Other event Filing —
June 17, 2026 A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis Trial Milestone Phase 1
June 2, 2026 8-K filed: Other event Filing —
May 28, 2026 8-K filed: Other event Filing —
May 6, 2026 Quarterly results filed (8-K) Earnings —
February 26, 2026 Quarterly results filed (8-K) Earnings —
November 10, 2025 8-K filed: Other event Filing —
November 10, 2025 ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension Trial Milestone Phase 3
November 5, 2025 Quarterly results filed (8-K) Earnings —
October 9, 2025 8-K filed: Material agreement, Acquisition completed Corporate —
August 27, 2025 8-K filed: Material agreement Corporate —
August 25, 2025 8-K filed: Material agreement, Reg FD disclosure Corporate —
August 6, 2025 Quarterly results filed (8-K) Earnings —
May 15, 2025 8-K filed: Leadership change Corporate —
May 8, 2025 Quarterly results filed (8-K) Earnings —
October 3, 2024 Afrezza® INHALE-1 Study in Pediatrics Trial Milestone Phase 3
March 26, 2024 INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes Trial Milestone Phase 4
October 17, 2022 Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes Trial Milestone Phase 4
May 28, 2021 Afrezza® Dosing Optimization Study Trial Milestone Phase 4
March 17, 2020 Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Trial Milestone Phase 2
June 5, 2018 Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.